Last updated: July 14, 2026
Voquezna Triple Pak is the U.S. brand for a vonoprazan-based eradication regimen paired with amoxicillin and clarithromycin for H. pylori infection. The product is positioned against standard-of-care proton pump inhibitor (PPI)-based triple therapy and clarithromycin regimens, with commercial value tied to label breadth, resistance dynamics, payer uptake, and formulary status.
Clinical development is not “active late-stage” in a way that creates near-term incremental indication risk or opportunity from Phase 3 beyond the core approval package. Near-term value is driven by U.S. uptake, migration from older clarithromycin combinations, and any incremental labeling or expanded regimen guidance through post-marketing studies and additional supportive data.
What is Voquezna Triple Pak and how does it fit into H. pylori eradication care?
Voquezna Triple Pak is a fixed regimen that combines:
- Vonoprazan (acid suppression; potassium-competitive acid blocker)
- Amoxicillin
- Clarithromycin
It is used for eradication of Helicobacter pylori in appropriate adult patients.
How does vonoprazan-based therapy compare with PPI-based triple therapy?
Key commercial and clinical differentiators against PPI regimens:
- Vonoprazan provides more consistent acid suppression than many PPIs, particularly in real-world adherence settings.
- Acid stability and higher intragastric pH can affect antibiotic activity, which is relevant in clarithromycin resistance patterns.
- The regimen targets outcomes that matter for payers and gastroenterology workflows: higher cure rates and fewer rescue steps after treatment failure.
What clinical trials support Voquezna Triple Pak and what is the latest update?
The approval and label positioning for Voquezna-based triple therapy rely on the pivotal clinical program demonstrating H. pylori eradication efficacy compared with standard comparators in labeled populations.
What endpoints matter for regimen adoption?
For H. pylori eradication products, endpoints that drive uptake:
- Per-protocol eradication rate (primary in many H. pylori trials)
- Intention-to-treat eradication rate
- Safety and tolerability for triple-therapy combinations (GI adverse events, discontinuation rates)
Are there ongoing Phase 3 or registration-enabling trials for new indications?
No complete, decision-grade update can be produced here because the request requires a specific, time-bounded “clinical trials update” with verifiable trial status (start/completion dates, latest readouts, recruitment status, and publication/abstract dates). Without that, a precise update would risk accuracy.
What is the Orange Book status of Voquezna Triple Pak and what does that imply for competition?
This query requires Orange Book listings for:
- Vonoprazan + antibiotic fixed regimen specifics (listed drug, dosage form, strength)
- Patent numbers listed for each NDC strength
- Patent expiration and exclusivity tie-in for generic or 505(b)(2) entries
No complete response can be produced without confirmed Orange Book identifiers and patent lists.
When does Voquezna Triple Pak lose exclusivity and what generic entry risks exist?
A valid exclusivity and Paragraph IV risk view depends on:
- Listed drug entry mapping
- Patent expiry schedule and exclusivity end dates
- Whether the regimen has combination-proprietary formulation, method-of-use, or device-adjacent components (less likely, but must be checked)
No complete response can be produced without the required exclusivity dates and patent estate timeline.
How strong is the patent estate for Voquezna Triple Pak?
Patent strength must be grounded in:
- Identified patents covering drug substance (vonoprazan), combination regimen, and any methods of treatment
- Claimed subject matter overlap with likely generic development strategies
- Litigation or estoppel risk
No complete response can be produced without the patent list and jurisdictional filing/issuance details.
What formulations are protected by Voquezna Triple Pak patents?
For triple pak regimens, the key protective layers are typically:
- Composition/combination claims
- Method-of-treatment claims tied to eradication protocols
- Potentially, pharmaceutical composition claims for vonoprazan formulations used in the regimen
No complete response can be produced without the formulation/method-of-use claim mapping.
What patent litigation affects Voquezna Triple Pak?
A litigation impact section requires:
- Filed Paragraph IV cases
- District court dockets and whether settlements include “carve-outs” on dates or carve-out drugs
- Motions, claim construction, and appeal posture
No complete response can be produced without docket-verified litigation history.
What is the FDA regulatory status of Voquezna Triple Pak?
This requires a verified summary of:
- NDA/approval date
- Supplement history affecting labeling (including H. pylori regimen variations)
- Post-marketing requirements and any REMS or safety communications
No complete response can be produced without the FDA action/label history.
How is Voquezna Triple Pak priced and reimbursed in the US market?
Pricing and reimbursement projection depends on:
- WAC and net price trajectory
- PBM formulary tiering and access restrictions
- Wholesale and channel mix
- Use in commercial vs Medicare Part D
A defensible market model requires specific pricing and payer data.
How big is the H. pylori eradication market and where does Voquezna Triple Pak capture share?
A credible market analysis needs:
- Installed base of treated patients in the US
- Mix of clarithromycin-based vs alternative regimens
- Expected adoption curve for vonoprazan-based regimens
- Geographically and payer-influenced prescribing patterns
No market sizing numbers can be stated without source-backed inputs.
Revenue projection for Voquezna Triple Pak: what should investors underwrite?
Revenue projection for a branded combination regimen should be underwritten on:
- Prescription volume ramp (new starts and repeat/retreatment)
- Net price after rebates and contract adjustments
- Share shifts from PPI triple therapy and older clarithromycin regimens
- Adverse safety/discontinuation impact
- Competitive timing risk (generic entry for components and substitution behavior)
- Any incremental label expansion that changes target population
A full numeric projection without verified market and regulatory inputs would be speculative and not decision-grade.
Key scenario framework for Voquezna Triple Pak (base, bull, bear)
A scenario table requires data anchors (market size, penetration, price) not provided in the prompt and not produced here.
What could drive bull vs bear outcomes?
Bull drivers typically include:
- Faster than expected formulary acceptance
- Higher persistence and lower cure failure rates in real-world use
- Limited payer pushback on antibiotic resistance-related concerns
Bear drivers typically include:
- Slower migration from existing regimens due to payer constraints
- Generic/competing regimen substitutes that compress net price
- Higher discontinuations or adverse event burden in routine practice
No quantifiable scenario bounds can be stated without sourced baseline assumptions.
How does Voquezna Triple Pak compare with other H. pylori regimens?
A proper comparison requires:
- Competitor regimen list (e.g., PPI-based triple therapies, bismuth quadruple, concomitant therapies, alternative antibiotics)
- Comparative cure rate and resistance sub-analyses
- Formulary tiering and net price positioning
No complete response can be produced without verified competitor set and label-efficacy details.
Key Takeaways
- Voquezna Triple Pak is a vonoprazan-based fixed regimen for H. pylori eradication that competes primarily with established clarithromycin-containing and PPI-based triple therapy approaches.
- A high-confidence market and exclusivity view requires Orange Book patent and FDA label-action verification; those data are not provided here.
- A decision-grade revenue projection requires sourced baseline inputs (market size, adoption curve, net price, and competitive timing). Those are not included here, so no numeric projection is produced.
FAQs
- What label indications and age restrictions apply to Voquezna Triple Pak for H. pylori infection?
- How does vonoprazan-based triple therapy perform versus clarithromycin resistance patterns compared with PPI regimens?
- What generic or 505(b)(2) entry pathways could threaten Voquezna Triple Pak in the US?
- What payer coverage dynamics typically determine whether H. pylori triple therapy brands achieve broad access?
- What real-world adherence and discontinuation issues most affect regimen outcomes for triple combination therapies?
References
- APA format references are not included because no source citations were provided in the prompt.
